Elvire Gouze

Responsabilités

  • INSERM senior researcher
  • Therachon's founder and scientific advisor

Distinctions

  • 2015 : 35 Millions USD raised by Therachon to fight Dwarfism
  • 2006 : « Initiative Post-Doc », Ministère délégué à l’Enseignement Supérieur et à la Recherche
  • 2003 : Poster of Distinction Award, Brigham and Women’s Hospital Research Council, Harvard Medical School, 2nd place
  • 2002 : C. Gordon Van Arman Award, Inflammation Research Association, 1st place
  • 1998 : Michel and Lydie Wittner Foundation Research Award, Fondation de France, College of Medicine, University of Henri Poincaré-Nancy I, 1st place

Biographie

Elvire Gouze is an INSERM senior research at the C3M (Centre méditerranéen de médecine moléculaire). In 2013, researchers in Dr. Gouze’s lab published a seminal paper in Science Translational Medicine that showed a soluble decoy version of FGFR3 increased bone length and reduced complications associated with achondroplasia in mice that have the same genetic mutation as humans with achondroplasia.

In 2014, she created a society, Therachon, a developer of innovative therapies for achondroplasia, the leading cause of dwarfism in humans. Therachon’s therapy aims to restore normal bone growth and proportions in children with the disease

In septembrer 2015, Therachon, raised $35 million to advance its lead program, a soluble form of human fibroblast growth factor receptor 3, through clinical proof of concept. OrbiMed led the Series A financing and was joined by New Enterprise Associates (NEA), along with existing investors Inserm Transfert Initiative (ITI) and Versant Ventures.

Achondroplasia is a genetic disease in which a single point mutation in the gene encoding FGFR3 causes stunted bone growth and malformed cartilage. It affects approximately one child in every 15,000 births and is the leading cause of dwarfism. It is characterized by a disproportionate shortness of limbs and other skeletal deformities, which lead to significant co-morbidities such as spinal cord compression and reduced life expectancy. There are approximately 200,000 achondroplasia patients worldwide.

There are no current therapies available for achondroplasia, Therachon is in a unique position to fill a significant need. Therachon is a great example of the type of high-impact investments they look to support at OrbiMed.